Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) EBITDA (2016 - 2025)

Historic EBITDA for Heron Therapeutics (HRTX) over the last 14 years, with Q3 2025 value amounting to -$17.5 million.

  • Heron Therapeutics' EBITDA fell 26445.83% to -$17.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.6 million, marking a year-over-year increase of 5123.54%. This contributed to the annual value of -$13.6 million for FY2024, which is 8771.34% up from last year.
  • Per Heron Therapeutics' latest filing, its EBITDA stood at -$17.5 million for Q3 2025, which was down 26445.83% from -$2.4 million recorded in Q2 2025.
  • In the past 5 years, Heron Therapeutics' EBITDA registered a high of $3.6 million during Q4 2024, and its lowest value of -$63.9 million during Q1 2022.
  • For the 5-year period, Heron Therapeutics' EBITDA averaged around -$28.6 million, with its median value being -$25.0 million (2023).
  • Over the last 5 years, Heron Therapeutics' EBITDA had its largest YoY gain of 18251.02% in 2025, and its largest YoY loss of 26445.83% in 2025.
  • Heron Therapeutics' EBITDA (Quarter) stood at -$54.6 million in 2021, then soared by 63.71% to -$19.8 million in 2022, then surged by 45.99% to -$10.7 million in 2023, then soared by 133.95% to $3.6 million in 2024, then tumbled by 581.13% to -$17.5 million in 2025.
  • Its EBITDA stands at -$17.5 million for Q3 2025, versus -$2.4 million for Q2 2025 and $2.6 million for Q1 2025.